2-Butoxybenzenemethanamine | 37806-35-2

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Butoxybenzenemethanamine
• 英文别名: (2-butoxyphenyl)methanamine
• CAS: 37806-35-2
• 化学式: C₁₁H₁₇NO
• mdl: MFCD09734334
• 分子量: 179.262
• InChiKey: WCOVIZQJJBFANW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Butoxybenzenemethanamine 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.17h， 生成
  参考文献：
  名称：

  Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity

  摘要：

  Activation of protease activated receptor 2 (PAR2) has been implicated in inflammatory and metabolic disorders and its inhibition may yield novel therapeutics. Here, we report a series of PAR2 antagonists based on C-terminal capping of 5-isoxazolyl-L-cyclohexylalanine-L-isoleucine, with benzylamine analogues being effective new PAR2 antagonists. 5-Isoxazolyl-L-cyclohexylalanine-L-isoleucine-2-methoxy-benzylamine (10) inhibited PAR2-, but not PAR1-, induced release of Ca2+ (IC50 0.5 mu M) in human colon cells, IL-6 and TNF alpha secretion (IC50 1-5 mu M) from human kidney cells, and was anti-inflammatory in acute rat paw inflammation (ED50 5 mg/kg sc). These findings show that new benzylamide antagonists of PAR2 have anti-inflammatory activity. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.12.048

文献信息

• [EN] BIARYL PYRAZOLES AS NRF2 REGULATORS<br/>[FR] BIARYL PYRAZOLES UTILISÉS COMME RÉGULATEURS DE NRF2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017060854A1

  公开（公告）日：2017-04-13

  The present invention relates to biaryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

  本发明涉及双芳基吡唑化合物、它们的制备方法、含有它们的药物组合物及其作为NRF2调节剂的应用。
• INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150038523A1

  公开（公告）日：2015-02-05

  The invention relates to compounds of formula (I): wherein R 1 , R 2 , and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula (I) for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to alpha-V-beta-integrin antagonists to target cells expressing alpha-V-beta-3.

  本发明涉及式(I)的化合物，其中R1、R2和n在详细说明和权利要求中有定义。特别地，本发明涉及式(I)的化合物，用于制造和传递与α-V-β整合素拮抗剂连接的共轭基团，如小分子、肽、核酸、荧光基团和聚合物，以靶向表达α-V-β-3的细胞。
• PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL
  申请人：Mitsubishi Gas Chemical Company, Inc.

  公开号：EP2657214B1

  公开（公告）日：2017-02-15
• CHIRALE CYCLOPLATINIERTE KOMPLEXE, HERSTELLUNGSVERFAHREN SOWIE DEREN VERWENDUNG IN MEDIZIN UND KATALYSE
  申请人：Rheinisch-Westfälisch-Technische Hochschule Aachen

  公开号：EP2220100A2

  公开（公告）日：2010-08-25
• METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF
  申请人：Englert Ullrich

  公开号：US20100267977A1

  公开（公告）日：2010-10-21

  The present invention relates to a process for preparing cycloplatinated platinum(II) complexes, platinum(II) complexes prepared by this process and the use thereof for the treatment of tumor diseases and/or hemo blastoses.